Description: In July 2014, Dimitry Khmelnitsky advised investors to sell Valeant Pharmaceuticals International Inc. and then watched the stock double in a year. “It was very painful,” Khmelnitsky, an analyst at Veritas Investment Research Corp., said in an telephone interview from his office in Toronto. “What I felt was pain.”
Source: Bloomberg.com – video report
Date: Mar 02, 2016
Questions for Discussions:
- What does this report say about the reasons for Valeant stock movements over the past few years?
- What lessons are there for investors and financial managers?
- What should investors do now?